SAB Biotherapeutics Inc (SABS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $266.66M
Last updated: Nov 17, 2026 at 11:05 AM ET
SAB Biotherapeutics Inc (SABS) Earnings: Report Dates and Results
SAB Biotherapeutics (SABS) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, SAB Biotherapeutics reported EPS of -$0.24, above the -$0.27 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
SABS has an expected report date of Mar 8, 2027.
SABS Earnings Call
The latest SABS earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 21 quarters below that had an estimate, SABS beat 8, missed 12 and matched 1. The widest gap in the table came in the quarter ended Dec 31, 2021, when EPS landed 500.00% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.24 | -$0.27 | -$0.32 - -$0.22 | +11.11% | Beat | -148.0% | 5 | 2 up, 0 down | Nov 5, 2026 | N/A |
| Jun 30, 2026 | -$0.28 | -$0.29 | N/A | +3.45% | Beat | N/A | 3 | 0 up, 0 down | Aug 6, 2026 | N/A |
| Mar 31, 2026 | -$0.35 | -$0.21 | -$0.31 - -$0.11 | -69.38% | Miss | N/A | 5 | 0 up, 0 down | May 12, 2026 | N/A |
| Dec 31, 2025 | -$0.41 | -$0.17 | -$0.17 - -$0.17 | -141.18% | Miss | N/A | 1 | 0 up, 1 down | Mar 9, 2026 | N/A |
| Sep 30, 2025 | $0.50 | -$0.46 | -$1.04 - -$0.14 | +208.70% | Beat | N/A | 6 | 1 up, 1 down | Nov 14, 2025 | N/A |
| Jun 30, 2025 | -$1.09 | -$0.82 | N/A | -32.93% | Miss | N/A | N/A | 0 up, 0 down | Aug 7, 2025 | N/A |
| Mar 31, 2025 | -$0.56 | -$1.07 | N/A | +47.66% | Beat | N/A | N/A | 0 up, 0 down | May 9, 2025 | N/A |
| Dec 31, 2024 | -$0.98 | -$1.21 | -$1.21 - -$1.21 | +18.93% | Beat | N/A | 1 | 0 up, 1 down | Mar 28, 2025 | $114698 |
| Sep 30, 2024 | -$1.12 | -$1.09 | -$1.14 - -$1.06 | -2.75% | Miss | N/A | 4 | 0 up, 0 down | Nov 6, 2024 | N/A |
| Jun 30, 2024 | -$0.79 | -$1.15 | -$1.24 - -$1.02 | +31.30% | Beat | N/A | 2 | 0 up, 0 down | Aug 8, 2024 | $263137 |
| Mar 31, 2024 | -$1.14 | -$0.98 | -$0.98 - -$0.94 | -16.33% | Miss | N/A | 2 | 0 up, 0 down | Apr 1, 2024 | $944575 |
| Dec 31, 2023 | -$3.38 | -$0.62 | -$0.64 - -$0.60 | -445.16% | Miss | N/A | 2 | 0 up, 0 down | Mar 29, 2024 | $305011 |
| Sep 30, 2023 | -$1.01 | -$1.15 | -$1.30 - -$1.00 | +12.17% | Beat | N/A | 3 | 0 up, 0 down | Nov 13, 2023 | $1.27M |
| Jun 30, 2023 | -$1.29 | -$1.45 | -$1.60 - -$1.30 | +11.03% | Beat | N/A | 2 | 0 up, 0 down | Aug 21, 2023 | $85518 |
| Mar 31, 2023 | -$1.48 | -$1.00 | N/A | -48.00% | Miss | N/A | 1 | 1 up, 0 down | Apr 14, 2023 | $581101 |
| Dec 31, 2022 | -$0.16 | -$0.16 | N/A | 0.00% | In line | N/A | N/A | 0 up, 0 down | Mar 31, 2023 | $2.16M |
| Sep 30, 2022 | -$1.83 | -$1.10 | -$2.30 - -$0.90 | -66.36% | Miss | N/A | 2 | 0 up, 0 down | Nov 15, 2022 | $3.59M |
| Jun 30, 2022 | -$1.50 | -$1.00 | N/A | -50.00% | Miss | N/A | 1 | 0 up, 0 down | Aug 10, 2022 | $6.35M |
| Mar 31, 2022 | -$1.35 | -$1.10 | N/A | -22.73% | Miss | -260.7% | 2 | 0 up, 0 down | May 12, 2022 | $11.80M |
| Dec 31, 2021 | -$0.66 | -$0.11 | -$0.18 - -$0.04 | -500.00% | Miss | N/A | 3 | 2 up, 0 down | Mar 29, 2022 | $11.06M |
| Sep 30, 2021 | -$1.20 | -$0.60 | -$2.70 - $0.70 | -100.00% | Miss | N/A | 3 | 0 up, 0 down | Nov 22, 2021 | $14.68M |
| Jun 30, 2021 | -$0.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 9, 2021 | $18.21M |
| Mar 31, 2021 | $0.84 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 2, 2021 | $16.93M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.56, after -$4.03 the year before. It was -$1.05 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.56 | N/A |
| Dec 31, 2024 | -$4.03 | N/A |
| Dec 31, 2023 | -$7.16 | N/A |
| Dec 31, 2022 | -$4.84 | N/A |
| Dec 31, 2021 | -$1.05 | N/A |
Earnings Calls
The only earnings call listed below, 2026Q3 for the period ended Sep 30, 2026, runs about 3,300 words across 12 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 3,319 | 12 |
2026Q3 Earnings Call
Opening remarks
Samuel Reich Chief Executive Officer Thank you, operator. Good morning, and thank you to everyone joining us for our third quarter 2026 earnings call. I'm joined today by Lucy To, our Chief Financial Officer, who will review the third quarter financial results. I'm also joined by Eddie Sullivan, our Co-Founder and President, and Alexandra Kropotova, our Chief Medical Officer. As we begin November, we recognize Diabetes Awareness Month and focus attention on the millions of people living with type 1 diabetes. We remain committed to advancing new medicines with the potential to change the course of the disease and improve the lives of those affected. That focus continues to drive our work at SAB BIO, and we're pleased to have you with us today to review the progress we made during the third quarter. We continue to execute on our priorities for SAB-142 with strong momentum in SAFEGUARD enrollment and the FDA granting Fast Track designation to SAB-142 for the treatment of new-onset Stage 3 type 1 diabetes. For context, SAB-142 is a fully human anti-thymocyte immunoglobulin designed to preserve insulin-producing beta cells in order to slow disease progression in autoimmune type 1 diabetes. It was developed using our proprietary Tc Bovine platform, which allows us to generate fully human, multi-specific antibodies without the need for human donors. Because SAB-142 is fully human, it has the potential to overcome key limitations of non-human approaches and enable safe redosing over the long term. We believe SAB-142 represents an opportunity to help people with type 1 diabetes redefine what a Stage 3 diagnosis can mean. SAB-142 is currently being evaluated in two clinical trials, the registrational Phase 2b SAFEGUARD study for those newly diagnosed with Stage 3 T1D and the investigator-led Phase 3 PRISE study for people up to two years from a Stage 3 T1D diagnosis. Let's start with an enrollment update for SAFEGUARD. The performance of our clinical team this quarter has been exemplary. In September, the study's Data Monitoring Committee approved the final step-down to children ages 5 to 11, helping to further accelerate enrollment. We continue to see strong interest in SAFEGUARD from both patients and investigators, and we're excited to share that the adult and adolescent cohorts are now fully enrolled and closed for screening. With that, we are reaffirming our guidance to complete enrollment of SAFEGUARD in Q4, with topline data expected in the second half of '27. Building on that progress, the PRISE study expects to dose the first patients this quarter. There are seven clinical sites planned across the United States, Europe, and the UK.
Frequently Asked Questions About SABS
When is SAB Biotherapeutics's next earnings date?
SAB Biotherapeutics's next earnings report is expected for Mar 8, 2027.
Did SABS beat earnings estimates last quarter?
Yes. SAB Biotherapeutics reported EPS of -$0.24 for the quarter ended Sep 30, 2026, above the -$0.27 estimate, a 11.11% surprise.
What EPS do analysts expect from SABS next quarter?
The consensus EPS estimate for SAB Biotherapeutics for the quarter ending Dec 31, 2026 is -$0.25 from 13 analysts, with estimates from -$0.30 to -$0.11.
How often does SABS beat earnings estimates?
SAB Biotherapeutics beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +5.80%.
SABS pages: Overview, Earnings, Forecast, Financials, Competitors